 |
Siro Clinpharm |
SIRO
Clinpharm
Private
Limited
(SIRO),
clocked
an
estimated
sales
revenue
of  202 crore for FY 2010-11 when compared
with 150 crore in 2009-10.
During early 2011, the CRO announced the launch of its operations in
Malaysia and also announced strategic alliances with CROs in South
Korea and Taiwan in 2010. The company is in the process of evaluating
Philippines and Thailand amongst other Asian countries for expanding
its clinical operations. SIRO has strategic alliances and partnerships
with several firms such as Clingene, Pfizer and with Fisher Clinical
services. SIRO is a member of Bundesverband Medizinischer
Auftragsinstitute, the German Federal Association of Contract Research
Organizations. SIRO's laurels include, conducting over 130 clinical
trails, recruiting over 20,000 clincial trial subjects, passing over
240 audits by sponsor QA teams and working on USFDA, EMEA, UK MHRA,
Korean FDA WHO Health Canada and DCGI submissions. |
| Founder
&
Chairman Dr Gautam Daftary |
||
|
21
|
Business: Offers clinical Trials services | |
| Start-up Year: 1996 | ||
| Address:
DIL
Premises,
Ground Floor, Swami Vivekanand Rd, Near Tatwagyan
Vidyapeeth, Ghodbhunder Rd, Thane (W)- 400607 |
||
| Tel: +91-22-25848000 Fax: +91-22-25848475 Website: www.siroclinpharm.com |
||
| Revenue: 202
crore* |
||
 |
Cadila Healthcare |
Cadila
Healthcare
clocked biotech revenues worth 190.59 crore for FY 2010-11 as
compared to the previous fiscal's revenue of 147.48 crore. Presently, the firm
has 15 biosimilars and two novel products in its pipeline. The company
is also looking at biobetters for the future growth and has dedicated
120 scientists for this purpose. Zydus Cadila acquired Italy-based,
Etna Biotech, and the firm's Zydus Research Center (ZRC), has been
working on strategic research collaboration with Prolong
Pharmaceuticals, US, and Karo Bio, Sweden and Eli Lilly. Zydus Cadila
has made swift progress on NME research and has 12 INDs in various
stages of clinical trials and several more INDs in pre-clinical
evaluation. The company also signed an agreement with Bayer HealthCare,
in January 2011, to set up a joint venture company, Bayer Zydus Pharma,
for the sales and marketing of pharmaceutical products in India.
|
| CEO Pankaj R Patel |
||
|
22
|
Business: Biologics and diagnostics |
|
| Start-up Year: 1995 | ||
| Address:
Cadila Healthcare Ltd., Zydus Tower, Satellite Cross Roads, Ahmedabad –
380015,Gujarat, INDIA |
||
| Tel: +91-79-26868100 Fax: +91-79-26862365 Website: www.zyduscadila.com |
||
| Revenue: 190.59
crore* |
||
 |
Tulip Group |
Tulip
Group
of companies clocked a total revenue of 185.63 crore for FY
2010-11 as against 182.48 crore in FY 2009-10. Revenues from
domestic
sales for FY 2010-11 were 128.23 crore, while the firm reported
exports worth 57.40 crore. During the fiscal, the
company made
investments worth 89.25 crore, including 1.67 crore in R&D,
20.25 crore in infrastructure and 30.01 crore on manpower. The group
has on its rolls a total staff of 1,033 people and consists of several
individual companies such as Tulip Diagnostics, Microxpress, Orchid
Biomedical Systems, Qualpro Diagnostics, Zephyr Biomedicals, Coral
Clinical Systems, BioShields, Tulip Marketing, Crest Biosystems and
Lilac Medicare. It also has marketing alliances with companies like
Monobind, US; Orgentec, Germany and TOSOH, Japan. The company's
products are distributed across 55 countries, it has a sales team of
325 personnel, has a customer base of over 15,000 and has 300
distributors. |
| CEO Dr Dilip Tripathi |
||
|
23
|
Business: Manufacture and marketing of in vitro Diagnostic reagents and kits | |
| Start-up Year: 1988 | ||
| Address: Gitanjali, Tulip
Block, Dr Antonio Do Rego Bagh, Alto Santacruz, Bambolim Complex
Post Office, Goa - 403 202, INDIA |
||
| Tel: (0832) 2458546-51 Fax: (0832) 2458544 Website: www.tulipgroup.com |
||
| Revenue: 185.63
crore* |
||
 |
GlaxoSmithKline
Pharmaceuticals |
GlaxoSmithKline
(GSK) Pharmaceuticals, an affiliate of GlaxoSmithKline Biologicals,
headquartered in Rixensart, Belgium, clocked an estimated sales of 163
crore in 2010-11 as compared to 123.34 crore in 2009-10. Today, GSK
has a market share of 20 percent in the total Indian private vaccine
segment. Vaccines contributed to nine to 10 percent of its total sales
in the current year and in the coming years the company is looking at a
growth of around 15 percent from its vaccines product portfolio. GSK
India has 14 vaccines in its product basket, including Boostrix
(tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccine, adsorbed) and Cervarix, (human papillomavirus vaccine (types
16 and 18)) among others. The company's vaccine facility in Nasik,
Maharashtra, is expected to witness an overhaul of 100 crore in the
next three years. The Nashik facility also accounts for half of GSK's
annual manufacturing capacity for its lymphatic filariasis (LF)
programme. |
| CEO Dr Hasit Joshipura |
||
|
24
|
Business: Sales of vaccines and biologicals | |
| Start-up
Year: 2001 |
||
| Address: Dr Annie Besant Road,
Worli, Mumbai-40030 |
||
| Tel: +91-22-24959205 Fax: +91-22-24914863 Website: www.gsk-india.com |
||
| Revenue: 163 crore* |
||
 |
Monsanto India |
Monsanto
India clocked revenue sales of 161 crore in FY 2010-11 as against
142.4 crore in 2009-10. Monsanto has been selling Bt cotton hybrids in
India for the last five years under Monsanto Holdings Private Limited
(MHPL). MHPL is focused on marketing Paras cotton hybrid seeds with
Bollgard and Bollgard Bt cotton technologies and Seminis vegetable
hybrid seeds. It was estimated that the company sold about 18 lakh
packets of Bollgard during the 2010 kharif season, which is an increase
of two lakh as comapred to the same period in the last year. Monsanto
has launched Project SHARE (Sustainable Harvest Agriculture, Resources,
Environment), a sustainable yield initiative with an NGO called the
Indian Society of Agribusiness Professionals (ISAP), to improve the
socio-economic conditions of 10,000 small-marginal corn and cotton
farmers in 1,100 villages in Andhra Pradesh, Maharashtra and Rajasthan
within four years. |
| Managing
Director Mr Amitabh Jaipuria |
||
|
25
|
Business: Production and sale of herbicides, hybrid seeds and pesticides | |
| Start-up Year: 1949 | ||
| Address: Ahura Centre, 5th Floor,
96, Mahakali Caves Road, Andheri (East), Mumbai -400 093 |
||
| Tel: +91-22-28246450 Fax: +91-22-26902121 Website: www.monsantoindia.com |
||
| Revenue: 161 crore* |
||
